Upper cervical cord area measurements and percentage changes
| Placebo (RR=7; SP=6) | INFβ (RR=13; SP=12) | p Value† | ||
|---|---|---|---|---|
| Values are mean (SD). | ||||
| †Difference in UCCA change between placebo and INFβ at each time point. | ||||
| *p < 0.05, **p = 0.001 v baseline. | ||||
| Placebo: patients on placebo at 18 months and received interferon treatment at 24 months (RRMS) and 36 months (SPMS) onwards; INFβ: patients on interferon throughout the study. | ||||
| MS, multiple sclerosis; RR, relapsing–remitting; SP, secondary progressive; UCCA, upper cervical cord area. | ||||
| Month 0 | UCCA (mm2) | 72.3 (12.3) | 77.6 (9.4) | |
| Month 6 | UCCA (mm2) | 71.1 (12.5)* | 75.9 (8.7) | |
| Change (%) | −1.7 (2.3) | −1.0 (3.6) | 0.56 | |
| Month 12 | UCCA (mm2) | 70.1 (11.6)* | 75.7 (9.3)* | |
| Change (%) | −2.8 (3.0) | −1.5 (3.3) | 0.23 | |
| Month 18 | UCCA (mm2) | 69.7 (11.8)* | 75.3 (8.9)* | |
| Change (%) | −2.9 (3.3) | −1.8 (3.6) | 0.21 | |
| Month 48 | UCCA (mm2) | 68.1 (11.6)** | 73.2 (8.1)* | |
| Change (%) | −5.7 (4.6) | −4.5 (5.6) | 0.35 | |